Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463126 | 1.00 | KMT2A (0.38) | KMT2AHAO1HRH4CYP11B2MIF | |
| SCHEMBL389567 | 1.00 | KMT2A (0.38) | KMT2AHAO1HRH4CYP11B2MIF | |
| SCHEMBL2382277 | 1.00 | KMT2A (0.38) | KMT2AHAO1HRH4CYP11B2MIF | |
| Water SCHEMBL2398687 | 0.98 | KMT2A (0.37) | KMT2AHAO1HRH4CYP11B2MIF | |
| SCHEMBL27721928 | 0.98 | KMT2A (0.37) | KMT2AHAO1HRH4CYP11B2MIF | |
| SCHEMBL27742479 | 0.98 | KMT2A (0.37) | KMT2AHAO1HRH4CYP11B2MIF | |
| SCHEMBL644676 | 0.98 | HRH4 (0.36) | KMT2AHAO1HRH4CYP11B2MIF | |
| SCHEMBL2633370 | 0.93 | — | — | |
| SCHEMBL1608843 | 0.89 | — | — | |
| SCHEMBL30864882 | 0.86 | ESR2 (0.38) | KMT2AHAO1KMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0389189-B1 | Diazepine antiallergy agents | PFIZER LTD (GB) | 1994-05-18 | — | — | EP | claimed |
| US-5008263-A | Platelet activating factor antagonists; antiallergens; antiinflammatory agents | PFIZER INC. (US) | 1991-04-16 | — | — | US | claimed |
| CN-1045783-A | Diaza class anti-allergy medicament | PFIZER (US) | 1990-10-03 | — | — | CN | claimed |
| EP-0389189-A2 | Diazepine antiallergy agents | Pfizer Limited (GB) | 1990-09-26 | — | — | EP | claimed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3728216-B1 | PYRAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11384067-B2 | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114478488-A | Hexahydrobenzene pyrazole cannabinoid receptor 2 agonist and application thereof | 海思科医药集团股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478488-A | Hexahydrobenzene pyrazole cannabinoid receptor 2 agonist and application thereof | 海思科医药集团股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| CN-1390864-A | Additional polymerization catalyst and its production process | SUMITOMO CHEMICAL CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6083969-A | 2,3-DIARYLPYRAZOLES FUSED WITH CYCLOALKANES AND CYCLOALKENES, USED AS CYCLOOXYGENASE-2 (COX-2) INHIBITOR | ORTHO-MCNEIL PHARACEUTICAL, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0389189-B1 | Diazepine antiallergy agents | PFIZER LTD (GB) | 1994-05-18 | — | — | EP | disclosed |
| US-5008263-A | Platelet activating factor antagonists; antiallergens; antiinflammatory agents | PFIZER INC. (US) | 1991-04-16 | — | — | US | disclosed |
| CN-1045783-A | Diaza class anti-allergy medicament | PFIZER (US) | 1990-10-03 | — | — | CN | disclosed |
| EP-0389189-A2 | Diazepine antiallergy agents | Pfizer Limited (GB) | 1990-09-26 | — | — | EP | disclosed |
| US-3957480-A | HERBICIDES | THE UPJOHN COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | KMT2A 2942/4885HAO1 2766/4885HRH4 1967/4885 |
| US-11384067-B2 | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR4, LPAR5 | KMT2A 1828/4885HAO1 1099/4885HRH4 17/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | KMT2A 2632/4885HAO1 3255/4885HRH4 2728/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | KMT2A 2632/4885HAO1 3255/4885HRH4 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.